Aardvark Therapeutics Announces Receipt of FDA Rare Pediatric Disease Designation for Prader-Willi Syndrome and Expands the Ongoing Phase 2 Clinical Trial

The FDA granted Aardvark Therapeutics a Rare Pediatric Designation for the use of ARD-101 in Prader-Willi Syndrome (PWS), a rare genetic disease characterized by extreme and unabating hunger. Aardvark’s Phase 2 trial of oral ARD-101 in young adults with PWS is now open for enrollment of additional subjects. SAN DIEGO, Aug. 3, 2023 /PRNewswire/ — Aardvark Therapeutics, … Read more